445 related articles for article (PubMed ID: 13129416)
1. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
3. Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
Hsu TC; Wang CC
J Comp Eff Res; 2019 Jan; 8(2):73-79. PubMed ID: 30560687
[TBL] [Abstract][Full Text] [Related]
4. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer.
Kim DJ; Kim TI; Suh JH; Cho YS; Shin SK; Kang JK; Kim NK; Kim WH
Yonsei Med J; 2003 Aug; 44(4):665-75. PubMed ID: 12950123
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
6. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Carmichael J; Popiela T; Radstone D; Falk S; Borner M; Oza A; Skovsgaard T; Munier S; Martin C
J Clin Oncol; 2002 Sep; 20(17):3617-27. PubMed ID: 12202662
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
9. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
Hoff PM; Lassere Y; Pazdur R
Drugs; 1999; 58 Suppl 3():77-83. PubMed ID: 10711845
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
[TBL] [Abstract][Full Text] [Related]
11. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
Murad A; de Andrade CA; Delfino C; Arikian S; Doyle J; Sinha N
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):128-35. PubMed ID: 9348585
[TBL] [Abstract][Full Text] [Related]
13. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
Lima AP; del Giglio A
Eur J Cancer Care (Engl); 2005 May; 14(2):151-4. PubMed ID: 15842464
[TBL] [Abstract][Full Text] [Related]
14. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
16. Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Yang TS; Wang JY; Tang R; Hsu KC; Chen JS
Jpn J Clin Oncol; 2002 Sep; 32(9):352-7. PubMed ID: 12417601
[TBL] [Abstract][Full Text] [Related]
17. Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer.
Chakrapee-Sirisuk S; Sinlarat P; Lohsiriwat D; Lert-Akayamanee N; Nimmanwudipong T; Srimuninnimit V; Vathanophas V; Arch-Yaemsuan P; Boonnuch W
J Med Assoc Thai; 2001 Aug; 84(8):1142-7. PubMed ID: 11758850
[TBL] [Abstract][Full Text] [Related]
18. UFT in the treatment of colorectal and breast cancer.
Sun W; Haller D
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):49-56. PubMed ID: 11219978
[TBL] [Abstract][Full Text] [Related]
19. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
